An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo
A phase 3 trial of Enzalutamide in prostate cancer, run by Astellas (Beijing) Pharmaceutical R&D Co., Ltd., active and no longer recruiting.
Overview
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) is a phase 3 interventional study registered as NCT04076059 by Astellas (Beijing) Pharmaceutical R&D Co., Ltd., with 180 participants enrolled, started 2019-09-11 and due to reach its primary completion in 2022-11-18. Interventions recorded: Enzalutamide, Placebo, Androgen deprivation therapy (ADT). Conditions listed: Metastatic Hormone Sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.
- TrialStudy of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Shares Astellas, Enzalutamide, Prostate cancer.
- TrialA Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Shares Astellas, Enzalutamide, Prostate cancer.
- TrialA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Shares Astellas, Prostate cancer.
- TrialZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Prostate cancer.
- TrialA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Shares Enzalutamide, Prostate cancer.
- TrialThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En
Shares Enzalutamide, Prostate cancer.